0K9 Stock Overview
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
FSD Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.43 |
| 52 Week High | CA$1.46 |
| 52 Week Low | CA$0.41 |
| Beta | 0.91 |
| 1 Month Change | -27.50% |
| 3 Month Change | -41.22% |
| 1 Year Change | -67.78% |
| 3 Year Change | -69.41% |
| 5 Year Change | -98.79% |
| Change since IPO | -97.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.7% | 2.5% | 1.8% |
| 1Y | -67.8% | -27.7% | 2.2% |
Return vs Industry: 0K9 underperformed the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: 0K9 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 0K9 volatility | |
|---|---|
| 0K9 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0K9's share price has been volatile over the past 3 months.
Volatility Over Time: 0K9's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 17 | Zeeshan Saeed | www.fsdpharma.com |
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.
FSD Pharma Inc. Fundamentals Summary
| 0K9 fundamental statistics | |
|---|---|
| Market cap | €17.51m |
| Earnings (TTM) | -€16.73m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs 0K9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.90m |
| Earnings | -US$17.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.3% |
How did 0K9 perform over the long term?
See historical performance and comparison